425: BioNTech Secures 81.74% of CureVac Shares in Exchange Offer

BioNTech SE announced the successful satisfaction of the minimum condition for its exchange offer for CureVac N.V., with 81.74% of shares tendered.

Summary

• BioNTech SE has satisfied the minimum condition for its exchange offer for all outstanding shares of CureVac N.V.
• 184,071,410 CureVac shares, representing approximately 81.74% of CureVac's issued and outstanding shares, were validly tendered and not properly withdrawn prior to the expiration of the initial offering period.
• All validly tendered shares have been accepted, and all closing conditions related to the completion of the post-offer reorganization have now been satisfied.
• BioNTech will proceed to deliver BioNTech American Depositary Shares (ADSs) or cash in lieu of fractional BioNTech ADSs to the holders of CureVac shares who have tendered their shares.
• A subsequent offering period has commenced, allowing remaining CureVac shareholders to tender their shares until December 18, 2025, at 12:01 a.m. Eastern Time.
• A post-offer reorganization will be initiated promptly following the expiration of the subsequent offering period, which will result in non-tendering holders of CureVac shares receiving BioNTech ADSs (and/or cash in lieu of fractional BioNTech ADSs).
• Non-tendering holders of CureVac shares who receive BioNTech ADSs pursuant to the post-offer reorganization will generally be subject to a 15% Dutch dividend withholding tax.
• Promptly after the completion of the post-offer reorganization, shares held by non-tendering CureVac shareholders will cease to be tradable on any national stock exchange and may be subject to additional transfer restrictions.

Sentiment

Score: 8

Explanation: The successful satisfaction of the minimum condition for the exchange offer for CureVac shares is a significant positive milestone for BioNTech, indicating the transaction is proceeding as planned and strengthening its strategic position in the immunotherapy and mRNA space.

Positives

• BioNTech successfully met the minimum condition for its exchange offer for CureVac, securing 81.74% of shares, indicating strong shareholder acceptance.
• The satisfaction of the minimum condition allows the transaction to proceed as planned, leading to the integration of CureVac into BioNTech.
• All closing conditions for the post-offer reorganization have been satisfied, ensuring a clear path to the full completion of the acquisition.
• Tendering CureVac shareholders will receive BioNTech ADSs, integrating them into a larger, diversified immunotherapy company with a broad pipeline.

Negatives

• Non-tendering CureVac shareholders will be subject to a 15% Dutch dividend withholding tax on the BioNTech ADSs received during the post-offer reorganization.
• Shares held by non-tendering CureVac shareholders will cease to be tradable on national stock exchanges and may be subject to additional transfer restrictions after the post-offer reorganization, potentially limiting liquidity.

Risks

• Uncertainties regarding the exact timing of the Offer and the subsequent corporate reorganization of CureVac.
• Uncertainties as to how many of CureVac's remaining shareholders will tender their shares in the subsequent offering period.
• The risk that competing offers or acquisition proposals for CureVac could still be made.
• The possibility that various conditions to the consummation of the Offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived.
• The possibility of a termination of the Purchase Agreement.
• Challenges in obtaining necessary regulatory approvals or obtaining them on acceptable terms or within expected timing.
• Potential disruption from the transactions on BioNTech's and/or CureVac's business, including their relationships with employees, business partners, or governmental entities.
• The risk that the Offer or other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated.
• The risk that litigation in connection with the Offer or other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities as a result of the Offer or other transactions.
• General industry conditions and competition, including political, economic, and business conditions such as interest rate, inflation, tariff, and currency exchange rate fluctuations, and ongoing geopolitical conflicts.
• The impact of regulatory developments and changes in the United States, Europe, and other regions, including with respect to tax matters and pharmaceutical industry regulation and health care legislation.
• Challenges and uncertainties inherent in new product development, ability to obtain or maintain proprietary intellectual property protection, safety, quality, data integrity, or manufacturing issues.
• Potential or actual data security and data privacy breaches.

Future Outlook

BioNTech expects to promptly deliver BioNTech ADSs to tendering CureVac shareholders and will initiate the post-offer reorganization following the expiration of the subsequent offering period. The reorganization will lead to non-tendering shareholders receiving BioNTech ADSs, subject to Dutch dividend withholding tax, and their CureVac shares ceasing to be tradable on national stock exchanges.

Management Comments

• BioNTech will now proceed to deliver BioNTech American Depositary Shares (ADSs) (and/or cash in lieu of fractional BioNTech ADSs) to the holders of CureVac shares who have tendered their shares, to close the transaction, as set out in more detail in the offer documents.
• The parties will initiate the post-offer reorganization as promptly as practicable following the expiration of the subsequent offering period.

Industry Context

This acquisition strengthens BioNTech's position as a global next-generation immunotherapy company, potentially expanding its pipeline and technological capabilities, particularly in mRNA-based therapies, by integrating CureVac's assets. This move reflects the ongoing consolidation and strategic partnerships within the biotechnology sector, driven by the pursuit of innovative therapies for cancer and infectious diseases.

Legal Proceedings

• The risk of litigation in connection with the Offer or other transactions contemplated by the Purchase Agreement, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Tendering CureVac Shareholders: Will receive BioNTech ADSs, becoming shareholders in BioNTech, and participating in the combined entity's future prospects.
• Non-Tendering CureVac Shareholders: Will receive BioNTech ADSs but will be subject to a 15% Dutch dividend withholding tax and their shares will cease to be tradable on national stock exchanges, potentially facing additional transfer restrictions.
• BioNTech Shareholders: The acquisition is expected to enhance BioNTech's pipeline, market position, and strategic capabilities in the immunotherapy and mRNA sectors.
• Employees (BioNTech & CureVac): Potential for disruption from the transactions and impact on relationships, followed by integration into the combined organization.
• Business Partners (BioNTech & CureVac): Potential for disruption from the transactions and impact on existing relationships, requiring careful management during integration.

Next Steps

• BioNTech will deliver BioNTech ADSs (and/or cash for fractional ADSs) to holders of tendered CureVac shares.
• The subsequent offering period will continue until December 18, 2025, for remaining CureVac shareholders.
• Initiation of the post-offer reorganization promptly after the subsequent offering period.
• Non-tendering CureVac shareholders will receive BioNTech ADSs (and/or cash) and their shares will cease to be tradable.

Key Dates

Recommendation

The successful completion of the minimum condition for the CureVac exchange offer is a strong positive signal, indicating BioNTech's strategic expansion is on track. This acquisition is expected to bolster BioNTech's pipeline and market position in the rapidly evolving immunotherapy and mRNA sectors. While risks associated with integration and market conditions exist, the successful execution of this key milestone suggests a strengthened long-term outlook for BioNTech, making it an attractive investment for growth-oriented portfolios.

Keywords

BioNTech, CureVac, Exchange Offer, Acquisition, Merger, Biotechnology, Immunotherapy, mRNA, SEC Filing, Corporate Action, Tender Offer